
Opinion|Videos|January 31, 2025
Common Adverse Events Part 2
Panelists discuss common adverse events associated with subcutaneous nivolumab, emphasizing the importance of monitoring for immune-related adverse effects and managing them proactively to ensure patient safety and treatment adherence.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































